



LKT Laboratories, Inc.

AZ-628

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: getinfo@lktlabs.com

Web: lktlabs.com

Product Information

Product ID A9662

CAS No. 878739-06-1

Chemical Name 3-(2-cyanopropan-2-yl)-N-(4-methyl-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)benzamide

Synonym

Formula C₂₇H₂₅N₅O₂

Formula Wt. 451.52

Melting Point

Purity ≥96%

Solubility DMSO 90 mg/mL (199.32 mM)


Water Insoluble

Ethanol Insoluble

Store Temp -20°C

Ship Temp Ambient

Description AZ-628 is an irreversible Raf kinase inhibitor that exhibits anticancer chemotherapeutic activity in vitro and in vivo. AZ-628 strongly inhibits tumor cell growth in cells exhibiting mutant (V600E) B-Raf, a mutation commonly found in a variety of cancer subtypes; this compound also inhibits growth in several cell lines that were resistant to most other Raf inhibitors. AZ-628 exhibits similar inhibition of B-Raf and c-Raf in vitro but appears to be selective for B-Raf in vivo.



Bulk quantities available upon request

Product ID	Size
------------	------

A9662	1 mg
-------	------

A9662	5 mg
-------	------

References Whittaker SR, Theurillat JP, Van Allen E, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. *Cancer Discov.* 2013 Mar;3(3):350-62. PMID: 23288408.

Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. *Cancer Res.* 2008 Jun 15;68(12):4853-61. PMID: 18559533.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.